The latest from Dr. Falk Pharma
Welcome to our Newsroom, providing you with the latest news, press releases, clinical trial announcements, events, and more from Dr. Falk Pharma.
Follow us on LinkedIn!
Rare Disease Day
As the experts in digestive and metabolic medicine, our focus is also on rare diseases.
18th Congress of ECCO
In Copenhagen, Denmark, from March 1 – 4, 2023.
Thank you very much!
Together we know more. Together we do more.
Initiation of Phase II Study of naronapride in patients with gastroparesis
Renexxion Ireland and Dr. Falk Pharma announce that the first patient has been treated
We wish you happy holidays and all the best for 2023
New Work in Freiburg
Pilot space to find out which elements & spaces work for us
Launch of Dr. Falk Pharma in Italy
We are pleased to introduce our Italian affiliate!
Collaboration and Licensing Agreement with Takeda and Zedira
To Develop First-in-Class Celiac Disease Therapy
Launch of Dr. Falk Pharma in France
We are pleased to introduce our French affiliate!
UEG Week 2022
Join us from October 8 – 11 in Vienna on booth no. 43 or virtually!
NAFLD: Phase 2a proof of concept study of ZED1227
Dr. Falk Pharma and Zedira announce trial start for the treatment of non-alcoholic fatty liver disease. First patient enrolled in April.
International Liver Congress™ in London
We are proud to be a sponsor and look forward to seeing you in person on our booth no. 69 or online, 22-26 June 2022!
Digestive Disease Week® 2022
We look forward to 2 exciting presentations on day 4 of this year’s DDW!
Have difficulty swallowing food?
Difficulty swallowing and pain while eating may be warning signs of eosinophilic esophagitis (EoE). The first EoE Day will be held on May 22, 2022.
Response to the Ukraine crisis
Dr. Falk Pharma supports APOTHEKER HELFEN e.V.
Future starts here
Plans for the future Falk Campus in Freiburg-Nord finalized.
Together we advance PR600
Investigational New Drug Application for PR600 expected in 3Q 2022.